244 related articles for article (PubMed ID: 34256606)
1. Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs.
Weiser M; Davis JM; Brown CH; Slade EP; Fang LJ; Medoff DR; Buchanan RW; Levi L; Davidson M; Kreyenbuhl J
Am J Psychiatry; 2021 Oct; 178(10):932-940. PubMed ID: 34256606
[TBL] [Abstract][Full Text] [Related]
2. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
5. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
Kreyenbuhl J; Slade EP; Medoff DR; Brown CH; Ehrenreich B; Afful J; Dixon LB
Schizophr Res; 2011 Sep; 131(1-3):127-32. PubMed ID: 21576008
[TBL] [Abstract][Full Text] [Related]
6. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
7. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
Okada Y; Inada K; Akazawa M
Schizophr Res; 2023 Feb; 252():300-308. PubMed ID: 36706475
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
10. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
11. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Olfson M; Gerhard T; Huang C; Lieberman JA; Bobo WV; Crystal S
Schizophr Bull; 2012 Jun; 38(4):845-53. PubMed ID: 21307041
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006.
Sernyak MJ; Rosenheck RA
Psychiatr Serv; 2008 May; 59(5):567-9. PubMed ID: 18451019
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
16. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
17. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.
Gaviria AM; Franco JG; Aguado V; Rico G; Labad J; de Pablo J; Vilella E
PLoS One; 2015; 10(10):e0139403. PubMed ID: 26427051
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.
Joo SW; Kim H; Jo YT; Choi YJ; Ahn S; Lee J
Psychol Med; 2023 Jan; 53(1):181-188. PubMed ID: 33855950
[TBL] [Abstract][Full Text] [Related]
19. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
